Tissue Regenix: Poised for growth

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. In the past two years, the focus has been on its commercial strategy, restructuring to service demand, and commencing a capacity expansion programme in its US facilities. Phase 1 of the expansion programme has been completed, which, together with the potential return of elective surgeries following the pandemic, positions TRX well for growth and profitability.

  • Strategy: TRX is building an international regenerative medicine business around its proprietary technology platforms, underpinned by compelling clinical outcomes. Work has begun to expand production capabilities, enabling the business to grow its distribution networks, via strategic partnerships, to drive sales momentum.
  • Capacity expansion: Phase 1 has been completed through the creation of a new freezer facility (3x capacity) and by moving the distribution and supporting staff into the new facility. This has freed up space in the existing facility to add two new clean rooms, which have come on stream on time and on budget.
  • Positioning: Through its established network of relationships and distributors, there is strong underlying demand for TRX’s products. The 50% increase in manufacturing capacity will be coming on stream around the time that there is expected to be a return in elective surgeries, positioning TRX for 2H’21 growth.
  • Risks: The main risk is predicting the timing and pace of recovery from the global pandemic, as well as a recovery in the number of elective surgeries. While all the signals are pointing in the right direction, there can be no certainty that this will occur during 2021. Consequently, TRX is maintaining a cautious stance.
  • Investment summary: Tissue Regenix Group has a portfolio of innovative regenerative products with regulatory approval in both the US and EU. Realignment of its commercial strategy to maximise sales through strategic and distribution partnerships has been successful, resulting in increased demand for its products. TRX is scaling up its manufacturing capacity to meet this pending demand, leaving it well positioned to deliver sales growth when surgeries return, which should result in a re-rating.

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Tissue Regenix: Turning profitable and cash-generative

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative medicine products

    Hardman & Co

    Tissue Regenix: Operating leverage

    Tissue Regenix Group plc (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of regenerative medicine products for

    Hardman & Co

    Tissue Regenix: Strong 1H’22 sales suggest upside potential

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine

    Hardman & Co

    Tissue Regenix: On pathway to sustainability

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine

    Hardman & Co

    Tissue Regenix: Faster-than-anticipated recovery

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine

    Hardman & Co

    Tissue Regenix Poised for Growth (Analyst Interview)

    Tissue Regenix Group Plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joined DirectorsTalk. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance,

    Hardman & Co

    Tissue Regenix Group: Funded through to profitability

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary decellularisation technologies for repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of approved regenerative medicine products

    Hardman & Co

    Tissue Regenix Restructured to satisfy product demand

    Tissue Regenix Group (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix Credit facilities expand cash runway to 2021

    Tissue Regenix (LON: TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix Expanded GPO coverage secured

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix 2018 in review: foundations laid for osteobiologics

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse).

    Hardman & Co

    Tissue Regenix Group Dual revenue stream growth

    Tissue Regenix Group Plc (LON:TRX) has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has